ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers

This is an open-label, single-arm, investigator-initiated study conceived as a dose expansion cohort of the study D3-002, which evaluated ETC-159 in combination with pembrolizumab in solid tumors.

Trial Details

NCT ID
NCT06513624
Phase
PHASE1
Sponsor
National University Hospital, Singapore
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • ETC-159
  • Pembrolizumab
  • Denosumab / Zoledronic Acid
Locations (sample)
  • Singapore, Singapore, Singapore|1.28967,103.85007
  • Singapore, Singapore|1.28967,103.85007

Key Eligibility Criteria

  • Is capable of understanding the written informed consent, provides signed and witnessed written informed consent, and agrees to comply with the pro…
  • Is female, and age 21 years or older (Singapore sites) at pre-screening or screening.
  • Has histologically or cytologically confirmed, advanced or metastatic ovarian cancer with a platinum free interval of less than 6 months from prior…
  • Has MSS/pMMR tumors as determined by immunohistochemistry (IHC), polymerase chain reaction (PCR), or next-generation sequencing (NGS).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →